C-CAMP—GARDP collaborating to tackle global health threat of antimicrobial resistance
Centre for Cellular and Molecular Platforms (C-CAMP) has joined forces with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the global problem of resistant bacterial infections. Both parties have a joint aspiration to assist in fast-tracking the clinical development, validation and integration of innovative diagnostic solutions for antimicrobial resistance (AMR) into the health system for access by end-users including clinicians, laboratories, and hospitals.
The letter of intent was signed on 5 December 2022 at the C-CAMP office by Dr. Taslimarif Saiyed, CEO-Director of C-CAMP, Dr. François Franceschi, Head of Asset Evaluation and Development at GARDP, and Dr. Subasree Srinivasan, GARDP Medical Director.
This letter of intent underlines C-CAMP’s growing prominence as a global destination for cutting-edge AMR innovations. Dr. Saiyed welcomed this signing, saying, “This collaboration would allow C-CAMP to leverage its significant network in the Indian innovation ecosystem to identify, nurture, and scale up innovative solutions in India and beyond. Our collaboration with GARDP will help especially in clinical development and validation of C-CAMP-supported AMR solutions, with the larger goal of driving sustainable and ethical access to emerging technologies. This access will be crucial to bending the growing curve of AMR in India and abroad.”
“The Letter of Intent with C-CAMP recognizes the significant role India plays in providing global AMR solutions.” said François Franceschi. “It is an important opportunity to explore synergies in evaluating and providing feedback for the clinical development of urgently needed innovative diagnostic solutions to help tackle AMR globally, with emphasis on solutions that are also deployable in low- and middle-income countries.”
About GARDP:
The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created in 2016 by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. It aims to develop new treatments to fight drug-resistant infections, with a focus on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children. GARDP is funded by the governments of Australia, Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, the Canton of Geneva, as well as Médecins Sans Frontières and private foundations. GARDP is registered under the legal name GARDP Foundation. www.gardp.org
